Pulmonary vascular disease & thromboembolism
Integrative Multiomics in the Lung Reveals a Protective Role of Asporin in Pulmonary Arterial Hypertension
An erratum to this article was published (Circulation, 8 Apr 2025 ↗)
Authors' conclusion
Our integrative systems biology approach to dissect the PAH lung transcriptome uncovered asporin as a novel protective target with therapeutic potential in PAH.
Study context
- Population
- Human pulmonary arterial hypertension (PAH) and control lung samples (multicenter biobank); Sugen-hypoxia rats
- Participants
- 96 vs 52
- Comparison
- PAH vs control lungs
- PAHn = 96
- Controln = 52reference
Methodological detailsmulticenter lung biobank, integrative multiomics
- Multicenter lung biobank
- Integrative multiomics
Main finding
As reported in the abstract
- 2 potentially protective gene network modules associated with vascular cells identified
- ASPN (asporin) validated as key hub gene, upregulated as compensatory response to counteract PAH
- Asporin upregulated in lungs and plasma of multiple independent PAH cohorts; correlates with reduced PAH severity
- Asporin inhibits proliferation and TGF-β/phosphorylated SMAD2/3 signaling in PAH pulmonary artery smooth muscle cells
- Sugen-hypoxia rats: ASPN knockdown exacerbated PAH; recombinant asporin attenuated PAH
Original publication
Integrative Multiomics in the Lung Reveals a Protective Role of Asporin in Pulmonary Arterial Hypertension. Circulation. Published 21 August 2024. doi:10.
Summarised from the published abstract; every number is checked against it